TSE •
Healthcare •
Biotechnology •
Quote as of 06/12/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeTSE
Market Capitalization8,198.59 mln
Float36.38 mln
Earnings Date04/11/2025
Piotroski F-Score
2
/ 9
Weak
Relative Strength
10
/ 100
Significantly lagging
Debt / Equity
0.00
Debt-free
ROE
-54.13
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
Chordia Therapeutics is a Japanese biotechnology company founded in 2017 and headquartered in Fujisawa, focused on developing new medicines to fight cancer. The company's approach centers on correcting abnormal RNA activity within cancer cells, a mechanism that drives tumor growth. Its pipeline includes several drug candidates at various stages of development, with its lead compound CTX-712 currently being tested in early-stage human trials for patients with hard-to-treat cancers.
